NCT03139032View on ClinicalTrials.gov

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

July 17, 2017

Primary Completion Date

December 6, 2017

Study Completion Date

December 6, 2017

Conditions
Inflammatory Bowel DiseasesSkin Extra-intestinal Manifestations
Interventions
DRUG

APD334

APD334 active treatment for 12 weeks.

Trial Locations (3)

Unknown

Arena 2001, Leuven

Arena 1001, Hamburg

Arena 3001, Belgrade

Sponsors
All Listed Sponsors
lead

Arena Pharmaceuticals

INDUSTRY

NCT03139032 - Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations | Biotech Hunter | Biotech Hunter